Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Feb;62(1):121-37.
doi: 10.1016/j.pcl.2014.09.009.

Down syndrome preleukemia and leukemia

Kelly W Maloney  1 , Jeffrey W Taub  2 , Yaddanapudi Ravindranath  3 , Irene Roberts  4 , Paresh Vyas  5
Affiliations

Down syndrome preleukemia and leukemia

Kelly W Maloney et al. Pediatr Clin North Am. 2015 Feb.

Abstract

Children with Down syndrome (DS) and acute leukemias acute have unique biological, cytogenetic, and intrinsic factors that affect their treatment and outcome. Myeloid leukemia of Down syndrome (ML-DS) is associated with high event-free survival (EFS) rates and frequently preceded by a preleukemia condition, the transient abnormal hematopoiesis (TAM) present at birth. For acute lymphoblastic leukemia (ALL), their EFS and overall survival are poorer than non-DS ALL, it is important to enroll them on therapeutic trials, including relapse trials; investigate new agents that could potentially improve their leukemia-free survival; and strive to maximize the supportive care these patients need.

Keywords: B-ALL; Down syndrome; GATA1; Leukemia; Myeloid leukemia of Down syndrome; Preleukemia; Transient abnormal hematopoiesis/transient myeloproliferative disorder.

PubMed Disclaimer